Paolo Tarantino on X: "EMERALD trial: significant, albeit modest PFS improvement with elacestrant vs AI/fulvestrant in ET-pretreated MBC patients Good tolerability for elacestrant, with main AE being nausea. Could become the first
EMERALD Trial | ORSERDU™ (elacestrant) Efficacy
EMERALD Pancreas — Department of Oncology
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology
EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer
EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting
Elacestrant Impresses in EMERALD Trial of Breast Cancer
Overview of the EMERALD Trial of Elacestrant in ER+, HER2- Advanced Breast Cancer
On trial: Emerald Insight Expert Briefings - Library Matters
The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes
EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer | Future Oncology
Top Insights from the EMERALD Trial: Advanced Breast Cancer
ARV-trial.com Switch to D/C/F/TAF EMERALD Study ppt download
EMERALD Study Orkin C. Lancet HIV. 2018 Jan;5(1):e23-e34.
EMERALD Pancreas — Department of Oncology
EMERALD Trial | ORSERDU® (elacestrant) Efficacy
SABCS 2022: EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting
Gem Enhancement | ExCel Process| Emerald Treatment | Gemstone Emerald Ehancement Treatment | Clarity Enhancement Labs
Elacestrant vs Endocrine Monotherapy in Advanced Breast Cancer: Phase III EMERALD Trial - The ASCO Post
Laila Agrawal, MD on X: "Results from #EMERALD with oral #SERD elacestrant presented at #SABCS21. Improved PFS from 2.79 to 1.91 mo with greater separation at 6mo and 12mo. I had the
Imfinzi (durvalumab) plus bevacizumab met endpoints in EMERALD-1 Phase III results in Liver Cancer - YouTube
